Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moses Elisaf

Showing results (241-250 of 248) with videos related to

Pageof 25
Sort By:
You have reached the last page of results.This site can display upto 248 results.
Current Vascular Pharmacology|May 21, 2011
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summaryDimitri P Mikhailidis, Moses Elisaf, Manfredi Rizzo, et al.
Current Vascular Pharmacology|May 21, 2011
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclassesDimitri P Mikhailidis, Moses Elisaf, Manfredi Rizzo, et al.
Journal of Hypertension|April 11, 2018
Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatmentVasilios Kotsis, Jens Jordan, Dragan Micic, et al.
Journal of Hypertension|April 14, 2018
Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part B: obesity-induced cardiovascular disease, early prevention strategies and future research directionsVasilios Kotsis, Konstantinos Tsioufis, Christina Antza, et al.
European Heart Journal Supplements : Journal of the European Society of Cardiology|May 24, 2017
Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemiaRoberto Ferrari, Carlos Aguiar, Eduardo Alegria, et al.
Atherosclerosis. Supplements|August 29, 2015
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapyCarlos Aguiar, Eduardo Alegria, Riccardo C Bonadonna, et al.
Hormones (Athens, Greece)|April 19, 2016
Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsApostolos Achimastos, Theodoros Alexandrides, Dimitrios Alexopoulos, et al.
The New England Journal of Medicine|April 1, 2014
Darapladib for preventing ischemic events in stable coronary heart disease, Harvey D White, Claes Held, et al.
Pageof 25

Showing results (241-250 of 248) with videos related to

Sort By:
Pageof 25
You have reached the last page of results.This site can display upto 248 results.
Current Vascular Pharmacology|May 21, 2011
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summaryDimitri P Mikhailidis, Moses Elisaf, Manfredi Rizzo, et al.
Current Vascular Pharmacology|May 21, 2011
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclassesDimitri P Mikhailidis, Moses Elisaf, Manfredi Rizzo, et al.
Journal of Hypertension|April 11, 2018
Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatmentVasilios Kotsis, Jens Jordan, Dragan Micic, et al.
Journal of Hypertension|April 14, 2018
Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part B: obesity-induced cardiovascular disease, early prevention strategies and future research directionsVasilios Kotsis, Konstantinos Tsioufis, Christina Antza, et al.
European Heart Journal Supplements : Journal of the European Society of Cardiology|May 24, 2017
Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemiaRoberto Ferrari, Carlos Aguiar, Eduardo Alegria, et al.
Atherosclerosis. Supplements|August 29, 2015
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapyCarlos Aguiar, Eduardo Alegria, Riccardo C Bonadonna, et al.
Hormones (Athens, Greece)|April 19, 2016
Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsApostolos Achimastos, Theodoros Alexandrides, Dimitrios Alexopoulos, et al.
The New England Journal of Medicine|April 1, 2014
Darapladib for preventing ischemic events in stable coronary heart disease, Harvey D White, Claes Held, et al.
Pageof 25